Results 11 to 20 of about 35,569 (305)

Glucagon-like peptide analogues for type 2 diabetes mellitus : systematic review and meta-analysis [PDF]

, 2010
Background Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis ...
Deepson S Shyangdan, Christine Clar, Pawana Sharma, Royle, Pamela L, Sharma Pawana, Royle Pamela L, Clar, Christine, Clar, C., Waugh, Norman R, Waugh Norman R, Pamela L Royle, Shyangdan Deepson S, Clar Christine, Waugh, Norman, Norman R Waugh, Sharma, Pawana, Shyangdan, D. (Deepson), Shyangdan, Deepson S, Royle, Pamela   +18 more
core   +1 more source

The therapeutic potential of glucagon-like peptide-1 receptor analogs for neuroinflammation in the setting of asthma [PDF]

Exploration of Asthma & Allergy
Glucagon-like peptide-1 (GLP-1) is a hormone that regulates blood glucose levels and is produced by the enteroendocrine glands in the large and small intestines in response to the consumption of foods that contain carbohydrates, fats, and proteins.
Courtney Lehman, Ray Stokes Peebles Jr
doaj   +1 more source

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

Nature Communications, 2022
Glucagon-like peptide-1 receptor (GLP1R) agonists are used to treat type 2 diabetes (T2D), and polyagonists targeting multiple hormone receptors are investigated as potential therapeutics for T2D.
Hongwei Jiang, Shuguang Pang, Yawei Zhang, Ting Yu, Meng Liu, Huan Deng, Li Li, Liqi Feng, Baili Song, Han Han-Zhang, Qingyang Ma, Lei Qian, Wenying Yang   +12 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity [PDF]

Hormone Research in Paediatrics, 2021
<b><i>Background:</i></b> Obesity treatment based on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) proved to limit morbidity and mortality in adult population. In children, optimizing lifestyle intervention (LSI) and reducing culpable environmental exposures represent the mainstay strategy for obesity prevention and ...
Mojca, Jensterle, Andrej, Janež
openaire   +2 more sources

Similarity between class A and class B G-protein-coupled receptors exemplified through calcitonin gene-related peptide receptor modelling and mutagenesis studies [PDF]

, 2012
Modelling class B G-protein-coupled receptors (GPCRs) using class A GPCR structural templates is difficult due to lack of homology. The plant GPCR, GCR1, has homology to both class A and class B GPCRs. We have used this to generate a class A–
Poyner, David, Reynolds, Christopher A., Hay, Debbie L., Poyner, David R, Barwell, James, Upton, Graham J.G., Poyner, David R., Reeves, Philip J., Upton, Graham J. G., Taddese, Bruck, Reeves, Philip J, Reynolds, Christopher A, Conner, Alex C., Hay, Debbie L, Conner, Alex C, Vohra, Shabana, Upton, Graham JG   +16 more
core   +1 more source

The role of ECL2 in CGRP receptor activation: a combined modelling and experimental approach [PDF]

, 2013
The calcitonin gene-related peptide (CGRP) receptor is a complex of a calcitonin receptor-like receptor (CLR), which is a family B G-protein-coupled receptor (GPCR) and receptor activity modifying protein 1.
Poyner, David, Reynolds, Christopher A., Hay, Debbie L., Poyner, David R, Karakullukcu, Z. Gamze, Woolley, Michael J, Barwell, James, Karakullukcu, Z Gamze, Poyner, David R., Smith, Kevin J., Taddese, Bruck, Reynolds, Christopher A, Conner, Alex C., Hay, Debbie L, Watkins, Harriet A., Watkins, Harriet A, Conner, Alex C, Smith, Kevin J, Woolley, Michael J.   +18 more
core   +1 more source

Exendin-4 attenuates pain-induced cognitive impairment by alleviating hippocampal neuroinflammation in a rat model of spinal nerve ligation

Neural Regeneration Research, 2020
Glucagon-like peptide-1 receptor has anti-apoptotic, anti-inflammatory, and neuroprotective effects. It is now recognized that the occurrence and development of chronic pain are strongly associated with anti-inflammatory responses; however, it is not ...
Shan-Shan Cui, Xiao-Bo Feng, Bing-Hong Zhang, Zhong-Yuan Xia, Li-Ying Zhan   +4 more
doaj   +1 more source

How glucagon-like peptide 1 receptor agonists work [PDF]

Endocrine Connections, 2021
In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk and renal complications in high-risk individuals with
Andreasen, Christine Rode, Andersen, Andreas, Knop, Filip Krag, Vilsbøll, Tina   +3 more
openaire   +3 more sources

Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heart

Physiological Reports, 2023
The inotropic effects of glucagon have been recognized for many years, but it has remained unclear whether glucagon signaling is beneficial to cardiac function.
Ross T. Lindsay, Philip Ambery, Lutz Jermutus, Andrew J. Murray   +3 more
doaj   +1 more source

Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists

Endocrinology Research and Practice, 2022
Glucagon-like peptide-1 is the most potent incretin secreted from the intestinal tract. It is synthesized by L-cells in the jejunum and distal ileum of the gastrointestinal system.
Dilek Tüzün
doaj